Quality Level
Assay
≥99% (HPLC)
form
powder
technique(s)
HPLC: suitable
impurities
≤0.5% Glucosamine (HPAE)
color
white to off-white
mp
172-180 °C
solubility
H2O: 50 mg/mL, clear to slightly hazy, colorless to very faintly yellow
storage temp.
room temp
SMILES string
Cl.N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@H](O)CO
InChI
1S/C6H13NO5.ClH/c7-3(1-8)5(11)6(12)4(10)2-9;/h1,3-6,9-12H,2,7H2;1H/t3-,4+,5+,6-;/m0./s1
InChI key
CBOJBBMQJBVCMW-NQZVPSPJSA-N
Looking for similar products? Visit Product Comparison Guide
General description
D-galactosamine (d-GalN) is a specific hepatotoxic agent metabolized particularly in hepatocytes. It is a 6-carbon amino sugar derived from galactose.
Application
D-(+)-Galactosamine (D-chondrosamine) has been used with lipopolysaccharides (LPS) to induce models of acute hepatic failure (LPS/D-GalN-induced liver injury, hepatitis) for therapeutic research to find new drugs.
D-(+)-Galactosamine hydrochloride has been used:
- for the surface binding of mannan-binding lectin (MBL) to modified mica surfaces
- in sterile phosphate buffer saline (PBS) before the intraperitoneal injection
- in mice for the generation of primary bone marrow-derived macrophages (BMDMs)
Biochem/physiol Actions
Galactosamine (Gal) induces hepatocyte death both by necrosis and apoptosis. It prevents the production of liver RNA via the production of uridine diphosphate hexosamines. D-galactosamine lowers the intracellular pool of uracil nucleotides and thereby prevents the production of RNA and proteins.
Other Notes
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yating Li et al.
Applied microbiology and biotechnology, 103(1), 375-393 (2018-10-23)
Acute liver failure is a drastic, unpredictable clinical syndrome with high mortality. Various preventive and adjuvant therapies based on modulating the gut flora have been proposed for hepatic injury. We aimed to explore the preventive and therapeutic effects of Bifidobacterium
Aoxiang Zhuge et al.
Applied microbiology and biotechnology, 104(17), 7437-7455 (2020-07-16)
Acute liver failure is a clinical emergency associated with high mortality. Accumulating evidence indicates that gut microbiota participates in the progression of liver injury, and preventive therapies based on altering gut microbiota are of great interest. Previous studies demonstrated that
Kaicen Wang et al.
mSphere, 5(1) (2020-01-31)
Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on Bifidobacterium longum R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of B. longum R0175 against acute
Shan-Shan Li et al.
Molecular immunology, 101, 10-18 (2018-06-01)
Acute liver failure is a devastating clinical syndrome with extremely terrible inflammation reaction, which is still lack of effective treatment in clinic. Suppressor of Cytokine Signaling 1 protein is inducible intracellular negative regulator of Janus kinases (JAK)/signal transducers and activators
Yulin He et al.
Stem cell research & therapy, 12(1), 396-396 (2021-07-15)
Effective treatments for acute-on-chronic liver failure (ACLF) are lacking. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have been applied in tissue regeneration and repair, acting through paracrine effects, cell fusion, and actual transdifferentiation. The present study was designed to investigate
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service